نتایج جستجو برای: sofosbuvir

تعداد نتایج: 1451  

Journal: :Clinical drug investigation 2016
Andrea Messori

Several cases of expensive drugs designed for large patient populations (e.g. sofosbuvir) have raised a complex question in terms of drug pricing. Even assuming value-based pricing, the treatment with these drugs of all eligible patients would have an immense budgetary impact, which is unsustainable also for the richest countries. This raises the need to reduce the prices of these agents in com...

Background and objective: Human is the only host of hepatitis C virus. This virus has a positive single stranded RNA and lipoprotein envelop that has 7 confirmed genotypes. According to studies, genotypes 1a, 3a and 1b are the most common genotypes in Iran. No effective vaccine against HCV infection has been developed instead, advances in antiviral treatment using drugs that directly affect spe...

Journal: :InterConf 2023

Acupuncture has been practiced widely for treating different medical conditions. The basis of the acupuncture method is doctrine points, one features which their unique electrical properties on measurement methods electropuncture diagnostics are based. purpose study was to explore possibilities a medicament testing technique determining daily doses antiviral drug Sofosbuvir and comparing tested...

2017
Loreta A Kondili Giovanni Battista Gaeta Maurizia Rossana Brunetto Alfredo Di Leo Andrea Iannone Teresa Antonia Santantonio Adele Giammario Giovanni Raimondo Roberto Filomia Carmine Coppola Daniela Caterina Amoruso Pierluigi Blanc Barbara Del Pin Liliana Chemello Luisa Cavalletto Filomena Morisco Laura Donnarumma Maria Grazia Rumi Antonio Gasbarrini Massimo Siciliano Marco Massari Romina Corsini Barbara Coco Salvatore Madonia Marco Cannizzaro Anna Linda Zignego Monica Monti Francesco Paolo Russo Alberto Zanetto Marcello Persico Mario Masarone Erica Villa Veronica Bernabucci Gloria Taliani Elisa Biliotti Luchino Chessa Maria Cristina Pasetto Pietro Andreone Marzia Margotti Giuseppina Brancaccio Donatella Ieluzzi Guglielmo Borgia Emanuela Zappulo Vincenza Calvaruso Salvatore Petta Loredana Falzano Maria Giovanna Quaranta Liliana Elena Weimer Stefano Rosato Stefano Vella Edoardo Giovanni Giannini

BACKGROUND Few data are available on the virological and clinical outcomes of advanced liver disease patients retreated after first-line DAA failure. AIM To evaluate DAA failure incidence and the retreatment clinical impact in patients treated in the advanced liver disease stage. METHODS Data on HCV genotype, liver disease severity, and first and second line DAA regimens were prospectively ...

2016
Swathi Iyengar Kiu Tay-Teo Sabine Vogler Peter Beyer Stefan Wiktor Kees de Joncheere Suzanne Hill

INTRODUCTION New hepatitis C virus (HCV) medicines have markedly improved treatment efficacy and regimen tolerability. However, their high prices have limited access, prompting wide debate about fair and affordable prices. This study systematically compared the price and affordability of sofosbuvir and ledipasvir/sofosbuvir across 30 countries to assess affordability to health systems and patie...

Journal: :Advances in pharmacology and pharmacy 2022

The current drug research techniques, combinatorial synthesis and high throughput screening, help in obtaining pre-evaluating thousands of compounds a short duration time. Among the selected compounds, best hit molecule becomes lead, likeness property helps to optimize selection. Lipinski's Rule five is most widely used filter pre-evaluation according with poor oral absorption low permeation ha...

Journal: :Annals of hepatology 2014
Karen V Silva-Vidal Nahum Méndez-Sánchez

analysis of sofosbuvir/ribavirin versus sofosbuvir/ simeprevir for genotype 1 hepatitis C virus in inter-feron-ineligible/intolerant individuals. Approximately 185 million people worldwide have chronic hepatitis C virus (HCV) infection, and more than 350,000 people die of HCV-related liver diseases each year. Until 2011, the standard of care for patients with HCV genotype1 (GT1) was pegylated i...

2017
Giovanni Guaraldi Roberto Rossotti Gabriella Verucchi Marcello Tavio Luisa Pasulo Barbara Beghetto Giovanni Dolci Giulia Nardini Lorenzo Badia Anna Magliano Maria Cristina Moioli Massimo Puoti Giovanna Travi Annamaria Pazzi Luciano De Carlis Alessandro Giacomoni Andrea Lauterio Iacopo Mangoni Stefano Di Sandro Fabio Ferla Stefano Fagiuoli Michele Colledan Giuliana Cologni Fabrizio Di Benedetto Giuseppe Tarantino Valentina Serra Giovanni Dolci

This retrospective study reports the data of sofosbuvir-based anti-hepatitis C virus treatment in 24 candidates and 24 recipients of liver transplantation coinfected with human immunodeficiency virus. Sustained virologic response was cumulatively 85% (90% and 100% in those treated with optimal schedules pre- and posttransplant, respectively).

2014
Eric G. Meissner Amy Nelson Miriam Marti Henry Masur Anu Osinusi Shyam Kottilil

Successful treatment of chronic hepatitis C virus infection can now be achieved using directly acting antiviral agents without interferon. We report a patient who achieved a sustained virologic response after 27 days of treatment with sofosbuvir and ribavirin. Identifying factors that allow for shorter treatment in some individuals is imperative.

Journal: :JAMA 2014
Mark S Sulkowski Susanna Naggie Jacob Lalezari Walford Jeffrey Fessel Karam Mounzer Margaret Shuhart Anne F Luetkemeyer David Asmuth Anuj Gaggar Liyun Ni Evguenia Svarovskaia Diana M Brainard William T Symonds G Mani Subramanian John G McHutchison Maribel Rodriguez-Torres Douglas Dieterich

IMPORTANCE Treatment of hepatitis C virus (HCV) infection in patients also infected with human immunodeficiency virus (HIV) has been limited due to drug interactions with antiretroviral therapies (ARTs) and the need to use interferon. OBJECTIVE To determine the rates of HCV eradication (sustained virologic response [SVR]) and adverse events in patients with HCV-HIV coinfection receiving sofos...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید